Project Grant K99CA307609
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $368,294 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period September 1, 2025 through August 31, 2028. This award supports the development of next-generation platforms for interrogating T cell receptor (TCR) specificity to identify and detect tumor antigens at the protein level. The project addresses a critical bottleneck in cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $119,172.00 under the Cancer Research Manpower program (CFDA 93.398) to support research addressing therapeutic response in non-small cell lung cancer (NSCLC). The project, initiated August 1, 2025, and completing July 31, 2027, focuses on developing computational approaches to integrate multi-modal and multi-omics biomedical datasets for improved...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded The Leland Stanford Junior University a Project Grant of $661,135 on June 1, 2026, with a completion date of May 31, 2029. The award supports research conducted in Palo Alto, California, led by principal investigators Crabtree, Kay, Gray, and Woyach to develop novel therapeutic approaches for chronic lymphocytic leukemia (CLL), particularly for patients with disease that has become...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $337,739 to The Leland Stanford Junior University, effective July 1, 2025, through June 30, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award supports the development and application of a novel molecular methodology for mapping intercellular protein trafficking in glioblastoma (GBM), the most common and aggressive primary brain tumor in adults. The research deliverables...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Stanford University a Project Grant totaling $271,548 on July 10, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support cancer research career development and training. The award, which extends through June 30, 2027, funds investigator-initiated research conducted at the university's Palo Alto, California facility. The Cancer Research Manpower program provides biomedical training opportunities and...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $584,521 Project Grant on August 8, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate subclonal determinants of radiation response in soft tissue sarcomas. The research will deliver three primary products: (1) identification and validation of epigenetic changes, including DNA methylation and chromatin accessibility alterations, that confer radioresistance to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a $593,557 Project Grant on March 18, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to support research through February 28, 2031. This grant funds the development of novel magnetic resonance (MR) methods to enable real-time measurement and control of BPM31510, an emerging lipophilic tumor therapy composed of Coenzyme Q10 incorporated into a lipid...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $226,294 under the Cancer Research Manpower program (CFDA 93.398) on July 3, 2025, with completion targeted for June 30, 2027. This award supports a five-year career development program for Dr. Chris McGinnis, Ph.D., designed to prepare him for an independent research career in cancer immunology. The primary deliverable is advanced postdoctoral research training at...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a $158,499 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on May 15, 2026, with completion targeted for April 30, 2028. This award supports investigator-initiated cancer research focused on investigating the role of CDKN2A in lung adenocarcinoma metastasis. The research employs CRISPR-Cas9 somatic genome editing and tumor barcoding technologies to develop and...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a Project Grant totaling $644,703 (awarded July 1, 2026, with completion anticipated June 30, 2031) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop an advanced bone marrow organoid (BMO) culture system for acute myeloid leukemia (AML) research. The project delivers a human bone marrow organoid culture methodology that preserves the native bone...
The National Cancer Institute (NCI) awarded a Project Grant of $137,266 to The Leland Stanford Junior University, effective July 1, 2026 through June 30, 2028, under the Cancer Research Manpower program (CFDA 93.398). This award supports research aimed at developing comprehensive profiling methodologies for T-cell lymphoma (TCL) tumors and tumor immunity to enable personalized therapeutic interventions. The project integrates advanced molecular and immunological techniques to address critical gaps in disease monitoring and treatment optimization for this aggressive malignancy with high relapse rates. The research deliverables encompass three primary objectives: (1) developing integrated disease monitoring approaches combining targeted sequencing, viral genome analysis, immune receptor profiling, and copy number variation detection in circulating cell-free DNA; (2) leveraging advanced epigenetic and transcriptomic methods to comprehensively profile tumor microenvironment immune dynamics and identify immunological factors driving TCL progression through both systemic and spatial tissue analyses; and (3) advancing preclinical evaluation capabilities through patient-derived organoid models for testing novel immunotherapy approaches. These research outputs are intended to improve prognostication, patient stratification, and therapeutic decision-making for T-cell lymphoma patients.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $137.3k | 6/12/26 |